

# (**FUSUN**PHARM) 复星医药

上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

#### 2014 FIRST QUARTERLY REPORT

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Chen Qiyu

C. G.

\* F .C, .C

.Ç

#### 1 IMPORTANT NOTICE

1.1 в	r	r. r		1. 4	r	mm 📑		m	ra r,
1 - 3	r	r m	<b>*m</b> *	rr		r.r.	r 🦻 r	,'3	
rm	, m		*m.*	r m	<b>.</b>	m	* A		 3
r.s.	b	r	, , ·	' r		m, , , , , , , , , , , , , , , , , , ,	, <b></b>	, <b>*</b>	

1.2 A rain a m a sa a n maa a rain a rain rain.

1, ... S. ... Sm. s. ... S. r. ... r. S. r. ... S. Gr. ... S. ... b. s. ...

# 2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDINGS OF THE COMPANY

 $2.1 \dots r$  . rm

- , 1 1 m3

	As at the end of the Reporting Period	As at the end of the previous year	Change recorded at the end of the Reporting Period compared with the end of the previous year (%)
· · · · · · · · · · · · · · · · · · ·	30,052,2,5,5,7.23	2, 5,10,/.1./	1
At 'Ar (r - r* , At 'Ar) ()	1 <sup>5</sup> , 2/, ., ., 1, /.1 <sup>5</sup>	1 <sup>5</sup> ,332,1/,,/3.03	1. 3
	From the beginning of the year to the end of the Reporting Period (Jan – Mar)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Mar)	Year-on-year change (%)
(N )	,02/,51/, 3	,15,31.5	<b>¬ 0.</b>
	From the beginning of the year to the end of the Reporting Period (Jan – Mar)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Mar)	Year-on-year change (%)
・、海 ・ 1年 準 (メ・ )	2, 5, ,/2 , 5, ./.	2,0 <sup>5</sup> , <sup>5</sup> , <sup>5</sup> , /1.2	2 .2

A Ar Ar . Ar r r .Am mr.,

- , 1 1 1 m/3 , . . .

Items	Current Amount (Jan – Mar)	Description
G r, r m , r rr 3 3	, 0,55, , 50./.	・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
G 3 m 2 1 b 3 1 3 1 3 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	1,000.00	
G . % r . % . % . % r m	11, ,5 0, 13.21	・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
Ar - , Ar m. % , % , % % Ar % r %	-1, 53,0.2.3/	
m/s.	-3., , 301,	
Im m r . Art . ( . Ar . )	_5, 02,0, 1 110,, /, .	

\_ : r.3

, ттря тэ , эт					/, ,2/0		
The shareholding status of the Top 10 shareholders							
Name of the shareholder	Capacity	Shareholding (%)	Total number of shares held	Number of restricted shares held	Number of shares pledged or frozen		
	m/s /s /s-	, 1.02	. 20, , 1,31,	0	, ,		
K LL LL	1. A. A	1, . ,	33 <sup>5</sup> , 1 <sup>5</sup> , 30	0	/		
		1.22	2,3,,/52	0	, ,		
re		0./.	1,21,/,/	0	, ,		
[		0./0	1/ ,000,000	0	, ,%		
, ., 3 rrr 11/, r		0.	1, , , / ,22	0	, ,		
		0. ,	1, ,302, , 0	0	, ,		
[		0.5	12, <sup>5</sup> ,51	0	, ,9		
mme . —		0.51	11,3/, ,5/.	0	, ,		
rb; -, % - % - 01 - 002;		0, 5	10,1, 2, , 0	0	, ,		

The shareholding status of the Top 10 unrestricted	d shareholders of tradable shar	es
Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
(Gr /_ ) .,	20, , 1,31,	r r r
K I (N )	33 <sup>5</sup> , 1 <sup>5</sup> , 30	. At A . A . TA TA
	2, ,3, ,,/52	r t t³
.rc —	1 ,2 1,/, /	r r r
[	1/,000,000	r r r
	1, , . / ,22	r r r³
> 1	1, ,502, 0	r r r.3
I + r , mm% , . — - + 3 +	12, <sup>5</sup> ,31,	v r r r/s
	11,5/, 5/.	o rrr
	10,1, 2, , 0	r r r3
	m Ar b.	.r
कर्न क्षेत्रका करका जिल्लामा अपने कराया । १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७ - १९८७		. Tr

#### 3 SIGNIFICANT EVENTS

5.1 mr mr mr mr mr Gr.

		Balance Sl	neet	
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
, r.÷/4rm.,	2,0, / , ,121.20	1,3/3,300, 2 .5	, / %	· · · · · · · · · · · · · · · · · · ·
- /¥rm.,	32 , 2 <sup>5</sup> , 31. 2	12 ,51/ ,1, 1./ 2	1 1%	
		Income State	ement	
	Current Amount	Amount of the last period	Ratio of	
Items	(Jan – Mar 2014)	(Jan - Mar 2013)	change	Reasons
v., Atr.	1,555,0 . , 3 . 3	1,1, 2,5,, 05.	3. %	、 、 、 、 、
A m r . %%, % %	<i>s</i> . 1,. 2 <sup>5</sup> ,2 2	2 , ,0/, ,110.1,	<sub>3</sub> 5 %	
.G r m .* r	1,5, 5,0 1.3	<i>52</i> , <sup>5</sup> 1, 2.,	_ 5 %	(3: . 3: . 3: 3: 3: r r (r >3: r )3r
[	, 01, 1, , , /, 2	2 <sup>5</sup> ,200,01 .1	, %	
, At 17年7年7年	.,./,00 <sup>5</sup>	1.,030, 3	_5_ %	rms (r. 18 m), srms r. rms (r. 18 m), sr. 1. 18 rm rs
I m/s. /s, /s /s	2,11. , , ,	0 0 . 0 .	5, %	reger of the second of the sec
. A miles e me	= , ,10 , \ 2. <sup>5</sup> .	2 <sup>5</sup> , , , ,/ 3, ./ 3	-s <sup>5</sup> 2%	

#### 4 APPENDICES

#### **Consolidated Balance Sheet**

31 M 2014

## , r > r > b Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

- , 1 1 1 1 1 1 2 1 1 3 1 1 1 1 1 1 3 1 3 1 1 3

Home	Closing balance as at the end	Opening balance as at the beginning
Current Assets:	of the Period	of the Year
	3,023, \(\cdot 0,\frac{5}{2}\) 3.0/	3,0 . , 13, 33. ,
b b · b · · · <sup>th</sup>	3,023, \ 0, \ 3.0/	3,0 . , 13, 33. ,
	, ~ ,1/3,/0	15//41
	1 1 1 1 5	3 <sup>5</sup> , 1., 5 <sup>11.</sup> /
r 3 6 3	3, /, 13,0, 1./ <sup>5</sup> 1, <sup>5</sup> , ,020, <sup>5</sup> /2.	1,2 3, /, , 1 . /
. r э r э г э г э г э г э г э г э г э г э	2 , ,103, , 0.3/	202,300,//, .2,
	2, , ,103, , 0.3/	202,300,77, .2,
ran m ras 6 s		
	1, 0	/22 4// 20
$\frac{(s-1)_{s}(s-1)_{s}}{(1-s)_{s}(s-1)_{s}(s-1)_{s}}$	1,5,,0, 1 <sup>5</sup> ,1,.,0 <sup>5</sup> ,./.	/ 22,3//.20 1 <sup>5</sup> ,1,,0 <sup>5</sup> /,
	$\frac{1}{3/2}, \frac{1}{2}, \frac{55}{3}, \frac{3}{3}$	
1. 2 2.4 2 3.4 2 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4	312,,0, 3	3/.,/.,31.
<u>г з з.</u> н	1 / /1 // 1	1, 1, ,2, 1, , , 5, ,30
	1, /., /1,3/1	1, 1, ,2, 1, , , .30
	3,50, ,302, ,	2 2 1 / 12
	, 20, ,35, 5, 5, 5, 502	, ,2, 2,1, /.12 , , , , , , , , , , , , , , , , , , ,
	. ,20. ,5 . , 1 .02	. , /. , , , 0/ .u
Non-current assets:		
	1,5, , /, / ,/ 2 /	1 2 / / 2
7 07 - 7	1,5, \ 9/\ 1,9/\ 2 /	1, . 2, . / . , 3. 2
, %m /r % m% .		
- Эт 1° 3° - 6, 3° - Эт 3° 1 - 3° т/° .	10.212 2.27 2	, 32,0 5,20 5
	10,212, 2, 23. 2	, 32,0 - ,20
[ 3 m3 , r , 3t 3		3,5/2,15/, 0.
	3, . /, /5,5, 3 1,3 <sup>5</sup> /, . <sup>5</sup> ,312.1/ . ,2 3, <sup>5</sup> 1 .1	$\frac{3,72,17,70.1}{1,321,0 \ 0,523. \ 1}$
fr , f f/3	1,5-7, \( \frac{1}{2}, \sqrt{51, 1}	
The state of the s	,2 3,5 1 .1	, ,251, , / .2
, r ,		
1 P. 3 3		

### **Consolidated Balance Sheet (Continued)**

31 M 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
, . r.=Am.,	2,0, / , ,121.20	1,3/3,300, 2.5
m · m · s s r · b ·		
3 rm rm 3 Ath 3		
rmb At		
b 3 - 3 - r.r		
b. 3	133, 20,3 0. 1	1, 5,5//,3, 3.35
, r 3, b,3	1,15 <sup>5</sup> , 2,21 <sup>5</sup> .	2 <sup>5</sup> , 22,21, 1
	200,2/0, 5	2 <sup>3</sup> , 22,21, , 1
_		
_'.s.s ww ` P''.s.	21. 5	25 25 24 24
, b, %	21/, \( \frac{5}{2}, \ldots, \)	$2^{5}3.0^{5}$ , $2/.2/$
b./s	2/2, 5 <sub>3</sub> ,1, 2, 110, <sup>55</sup> ,1/1.3	2//, 0, ,/ <sup>5</sup> /./. 1, . , <sup>55</sup> ,2 , .33
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	110, 55,1/1.3	,2/, ,003.
	1,21, ,/ 1, ,2, / .1/	1, 12,02 , 1.3 <sup>5</sup>
A St. b. F	1,21, ,/ 1, ,2, / .1/	1, 12,02 , , 1.3
I r r r r r r r r r r r r r r r r r r r		
m, r & % r & r	1	
militaria de la compania del compania del compania de la compania del compania del compania de la compania del compania de		
- m3 b 3 ,53		
.5()5(,)3, , , , , , , , , , , , , , , , , , ,	,	3 2
	<u> </u>	
	1	
	+	
	+	
	-	
	+	
	+	
	+	

#### **Balance Sheet of the Company**

31 M 2014

## , r. s h Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
b · b · . *	13,01 <sup>5</sup> , 03. 0	. 2/,131, /51
_ ,		
т,≉.э= Б,э=		
. r - %r/% % - 6.%		
[	s ,121, 0 . <sup>5</sup> .	2 ,55, ,/55,50
.β . Γ.β.β . β.β	1,5,22	2,55,,/55,50
。	1, \ 0,02/, <sup>55</sup> .1	1,/,/,210
[ 3. r3	51., 3.,.	5 <sub>1.,3.,</sub>
7 = 1,41,4 ( ) = 1,2 ( ) = 1, 2 ( ) = 1, 2 ( )		
v. 海r rm等。 - 漢	,000,000.00	2 5,000,000.00
	3, 3, 0, 2.1	3,0 2,01 <sup>5</sup> ,22 . <sup>5</sup>
Non-current assets:		
A by February States		
. %m ./r		
- /ārm r/s /s - 6//s		
-, %rm % ,	5, 23, 53,3 50	5,3/0,/, 5,5,2.
[ /3 m/3 . , r , 3r /3		
_ 3	1, 3/, 2, .1	20,1 5,0
.tr . , t -t.³		
, r , s ,		
, , , , , , , , , , , , , , , , , , ,		
, r ,		
I 6.3 3	2, 0 , 11./<	3,05,03,.52
\$ \$ 1 m \$ 1 \$ 1 m		
.G		
- शेरा के शेराके के ूक अपने		
(a) data (a) (a) (b) (b) (b) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c		
v.Ar −vm3. 3	3, 5 <sub>1</sub> ,, 5 <sub></sub> ,, 5	, ,0 2,/, , ,2/2, 0
2	د 0 , د ، 5, ، د, ،	.,,1,5,5
	13,13, ,23, ,03 , ,	12,55/, 32,10

#### **Balance Sheet of the Company (Continued)**

31 M 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:	01 011 0110 01	01 010 1001
, r = Arm ,	/ 10,000,000.00	± 0,000,000.00
_ , b, 3 3 r.r		
b.*		
. r . %. b. %		
78.85 B		
, , , , , , , , , , , , , , , , , , ,	5,,/50,,/3	0,/2, 11.3
b. 3	1. ,15. ,0. 5.02	22,22 ,5/
I 373 6.3	10. ,2. 2,/ . 0, .	1,,,5,,51,,
b./*		
	, ,1,,5 <sub>3</sub> ,,/	, 12, 23.5
m	0,000,000.00	0,000,000.00
%r · m% b %		
m3 b 3	1,0., 1 <sup>5</sup> ,1 <sup>5</sup> 3. 2	2, ,02, ,0 <sup>5</sup> 1.0 <sup>5</sup>
Non-current liabilities:		
- Arm ,	32 <sup>5</sup> ,000,000.00	12 <sup>5</sup> ,000,000.00
- b. <sup>3</sup> €	, ,0, 5, 2, ,3, 1, 3	, ,0, 3,3, 1,2, 0,
- Arm , b &		
A b. %		
is in the mass of the second o		
% - (m% b%	1, 5,000.00	2,0 <sup>5</sup> 0,000.00
· m³ b³	5,, 5, 5, 5, 5	, ,200, , 1,2, 0,
b 3	5,,51.,5,535	, , 2, , , , , 2, 1.5,
Equity attributable to the owners (or equity attributable to shareholders):		
, - , , (r - r* , , , )	2,2, ,5, ,5, .00	2,2,0, 2,3,.00
。	3,/、,20.,2.、.//	3,/, /1,2, 1
78 , 178 → 1 · · · 178		
。	, 5, ,/, 0,135.33	5, ,/, 0,155.33
.G* 3r . r , r		
	1,0 <sup>5</sup> , 22, 11.//	1,05, 31,0 1.32
	5, 1, 1, 1.0	., 31, ., ,///.0
	13,13, ,23, ,03 , ,	12,55/, 32,10

m, s, s

#### **Consolidated Income Statement**

*J* .€ – *M* 2014

#### r s h Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

- , 1 1m3 , 2, 2, 3 1 , - 1 3

Items	Current Amount	Amount of the Last Period
[	2, 5, ,/2, 5, ./.	2,0 <sup>5</sup> , 5/ <sup>5</sup> , /1.2
[ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]	2, <sup>5</sup> , ,/2, <sup>5</sup> , ./ <sub>5</sub> 2, <sup>5</sup> , ,/2, <sup>5</sup> , ./ <sub>5</sub>	2,0 <sup>5</sup> , 5/ <sup>5</sup> , /1.2
Links ms		
. r > , r/m / m		
_% mm m.%		
II	2,520, 5,30, 1	1, 2, , 3, , 1, ./3
$\Gamma(x) = \mu(x) X(x)$ .	2, <sup>5</sup> 20, , <sup>5</sup> ,30, . 1 1, <sup>555</sup> ,0, , 3, 3	$\frac{1, 2, 3, 5, 1 / 3}{1,1, 2,5, 3, 0.5}$
[ [3]3, [3], [3] [3]		
_33 mm 3_3 3		
rm m r		
m, 3°, 1., 3°		
· A · r · r · r · r · r · .		
* * * * * * * * * * * * * * * * * * *		
m r 73 r3 /r 33,3 /r3		
* 7 . 7 · * * · * · * · · · · *	1, , , . 2.2	1., 02,//2.1
<u> </u>	5 02,/ 31,211.12	, 0 <sup>5</sup> ,/02,
m r.33,33	<i>3</i> . 1, 2 <sup>5</sup> ,2 2	2. ,0/, ,110.1,
	2,/31,5/, .3	1, , 3.,210.
A 78 m rm.78 78	1,220,312. 0	32, <sup>5</sup> 1, 2, 2
I 3 m/3 m/3 ("-" )	1,5,5,0,1.3	
[ _ /* m/* _ m/* ("=" )	, 01, 1, , , / , 2	2. 5,200,011.
I	2, /,5, 0, , 2.15	1.3, ., , / 1
_ r* - * - ("-" )		
Ⅲ	5, 0,/,, ,0 2. 3	, s, 01,1, s. <sup>5</sup> ,
テルティーテ第1 - 1200年 第1 201 - 第200 第200 第	., , , /, 0, .0 <sup>5</sup>	1,030, 3
\$ , , -, \$	3,312, /0.	. 2. ,0 <sup>5</sup> 33
I m3	. 33, . 1.3	,550.05
[ r ("="	5, 5,000,2	52,/0, 523.
3, I m3, 3,3 3	2,11, ,	12,, 5
, , , , , , , , , , , , , , , , , , ,	, /2,//0,5 3, . 3	, 12, , 5,
. * . r r b . b . * * *	, 13, 1, ,/ 3, .12	<i>3</i> <sup>5</sup> 2,00. ,2.,. 1
.G /, 3 m r , r3 , 3r	. / , . 0, . / ./ 1	. 0, . 0, . 1
· [ r , 3r . r.]*		
(1) b 3 r x	0.1/	0.1
(2) , , , & r , & r.*	0.1/	0.1
· II. · · · · · · · · · · · · · · · · ·	= ,10 , 2.5.	2 <sup>5</sup> , , , , ,/ 3, ./ 3
· III m r · · · · m · · · m · ·	, 1/ , 0, . , 2.3	, 3. , , , , <sup>5</sup> , 1.20
m. r s s m/s . r b b . s s s s . m	351,515,1,5	3/ 0,/ <sub>×</sub> , ,0/ <sub>×</sub> .2 <sup>5</sup>
m, r/s /s /s /m/s . r b/ . b, /s . m / r /sr/s .	,2 <sup>55</sup> ,5,2	5,053,50,5

#### **Income Statement of the Company**

J .€ - M 2014

### Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Current Amount	Amount of the Last Period
r A . rr A		
, );		
A m n. n. paga paga	32,310,/1.5	20,/2, ,003.02
	-5,1 <sub>x</sub> ,20/, 1	/,20,,33,2
A m mm. m. s		
[, m. m. m. m. ("-" )	2/ ,10/ ,22/	2 , ,//1, / <sup>5</sup> , .
I in the indicate of the indic	2., 0., / 25./,	3, × <sup>5</sup> ,232, ×
II	-1,025,5,	2 5,/50,3, 5
プリング - 2年 - 1年年 1年 - 12年 1年 - 12日	5,000.00	,,032.
And the second s	2 0,000.00	5,11,2
I . (		
III r ("–"	-1,20/,5,	2 5,/, \ ,2 , .02
A I ma a a sa a		
	-1,20/,5,	2 5,/,,2,.02
(1) b 3 r , 3r r3	-0.00	0.12
(2) 3 3 r 3 r 13	-0.00	0.12
. [ 3r - m, r3-3 3 - m/s		5, ,2,
. II m r * . * m *	-1,20/,3,	2 5, 0/,513.32

m s i

#### **Consolidated Statements of Cash Flows**

*J* € - *M* 2014

### shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Current Amount	Amount of the Last Period
I. Cash flow generated from operating activities:		
ris is in the first in the second of the sec	3,03 <sup>5</sup> , 22, 1 <sup>5</sup>	2,5 33, /, ,0 3.55
. % r % % . r m + . m%r		
. ж. т. ж. в. т. н. ж. ж. т. в.		
. A r r m . Ar		
rss.s.,rmin r., ir s.r.		
. A 1/2 A		
. 3 13 3		
r% % % r m . %r% , %% mm		
rmb. A		
. A ra a r m ra r a br		
281 8 28	1/,/0 <sup>5</sup> ,/0	. ,2 . , 33./,
. A 19.3 19	. 0, , , , 2 . 3	3, ,3, ,, 0, /
, r b −	3,12 <sup>5</sup> ,, ,//1	3, ,3, 0, / 2, <sup>5</sup> , / <sub>2</sub> , , <sup>5</sup> /
r, r . r . r . 3r . 3r . 3r	1, 11,/13, ,3.	
, % 1% % / , m% ' ,		
- * 1** * * * ***		
rm3		
r Are, mm		
r., **		
r . % 6 % % . %m %%	,,, , 20,2 / . 0	313, <sup>5</sup> , , ,322, <sup>5</sup>
. 3 .3 .3 .	2,, 3/, 01.3 <sup>5</sup> ,/ <sup>5</sup> , 3, <sup>5</sup> 1.3,	2, 3,/23,22 ., .
- 10年 - 17年 - 17	, / <sup>5</sup> , . 3, <sup>5</sup> 1 .3,	5 3/,, 5, 1, 0
, r b −	3,11/, , , , , , , , /	2,501,51,32/
. №	3,11/, , x ,3, / . x . ,02/, <sup>5</sup> 1/, 3	$\begin{array}{c} 2, 3, /23, 22, \dots \\ 5_{3/3}, \dots, 5_{3/3}, 1, 0 \\ 2, 501, 51, 3 \dots 2/3 \\ \dots, 1, 5, 3, 1.5 \end{array}$
II. Cash flow generated from investing activities:		
r\$ 3. 3. r.m 3.m.\$., r\$ - 3r	1.,.1,10,.3	1.,, 3,/0.10
rss s rmrsir sms.	1.,.1,103	1,,,3,/0.10
. % . r% % . % r m	. ,/ 31, / <sup>5</sup> ./、	2,0 5,5 22.22
. % r % % r m 6 r % %r %r % m % .	3/, 1, 3.5.	
A 12 2 2 2 2	30,10 <sup>5</sup> ,000.00	5, 0,000.00
prb= r m ≥	2 , 5 5 ,131. 3	1. /, 2 <sup>5</sup> , 5 <sup>5</sup> .32
, r . r . r . r . 3 . 3 5 . 3 3 3 3 3 3 3 3 3 3 3 .	3. 3, 5 <sub>3</sub> , . , ./,	22 <sup>5</sup> , / 1,2 3.21
, r % , m /\$ .	5, 5/, /2.//	1,2/0,000.00
. # # # # # # .		
. A	, 1 , 10,//, , 0	, / 1, <sup>5</sup> 1. ,/、 2
2 (At ) 2 (18 ) (1 ) (8 )	. 1,2 1,12	1, , , , 5
, r (b=	//.,31,,55,,1	. 2. , . , / 21. 5
	= 3 , 1 , 2 , /	-5, ,,33,,0.,,3

#### **Consolidated Statements of Cash Flows (Continued)**

J .€ - M 2014

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
ra a r m r b.	5, ,1/0.00	
Li rasabib rarmama mr. Ara	5, ,1/0.00	
га запът	1,52,5,1,5	1. / ,0/、 , 02.00
r** * r m / b		
	21, 5,53	
y · b− · · · · · · · · · · · · · · · · ·	2,203,320. /	1. / ,0/、, 02.00
, r %, %m.*.	12 <sup>5</sup> ,2 <sup>5</sup> 3,2 3./3	1. , / 0,313.
r * rb/ * , r r %* , m*	20,22,./.3	1, ,2, 5, 00,
I	0,000,000.00	5 <sub>1,/2</sub> ,5 <sub>0,3</sub>
	1,3, 1.,	. ,25, ,0 2
, r b = r m	330,/ <sup>5</sup> , 0, .10	3 <sup>5</sup> 2, 3,2
. 74	1,5, 3, 1 .//	-1., , 03, .,
IV. Effects of exchange rate fluctuations on cash and cash equivalents	/,5,,	-, 0, , 3/
V. Net increase of cash and cash equivalents	3. ,000,201./ 3	= <sup>55</sup> , /2,13/.2
21. 1. 18 b. 18	2, 1, ,2 0,3/、.2	, ,1, 1,5, , , , 2.12
VI. Closing balance of cash and cash equivalents	2, 5 3,2 0,5 1.0	3, <sup>5</sup> , <sup>5</sup> , 2, 03./.

m s i

#### Statements of Cash Flows of the Company

J .€ - M 2014

### shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Current Amount	Amount of the Last Period
I. Cash flow generated from operating activities:		Dust 1 0110 u
r** * r m .		
	3,33 <sup>5</sup> ,/、2.12	1 <sup>5</sup> , ., ,10
, 16	3,33 <sup>5</sup> ,/, 2.12	15, . , ,10
r, r r r r r	2,00 , 2002	2 , 1 , , , 2 2 2 2 2
r . /*b/* /* /*m /**	2 ,/1 ,2/3. 5	21,, 5 32.32
\$ 18 18 1	15,55/,/10. 2	1.2 5
na n	/,00 , . 0, .	1,2.,,.,,5 11,,5,5,5,
, 16 r.m., 3r	50,3/, , 5.0	, 1, 1/, 33.30
	-, ., 0, /,/ . 2. ,	-2 ,02 ,323.5 3
II. Cash flow generated from investing activities:	, , , , , , , , , , , , , , , ,	_ ,=,,,======
r*3 3 rm 3 m/3 r* 3		
гзэг пгэл эмэ.	200, 0, ./5	1, 5,, 5, 3.00
. s reer m s e, . h.s e sr		
, -, Arm - A	50,000.00	3, ,23 , 2
is research in the residence to the second of the second o		
v. 海 ra a ra ca		
ρίβπου po r m u.β. po p. β	250, 0 ./5	1, 5, , , 0, , 2, 2
, r . r		5, 50.00
r % m/s.	31 <sup>5</sup> ,000,000.00	
. % , r . / / / / / / / / / / / / / / / / / /	2. ,023,100.00	5,0,,00.00
ν (Βτ		
, ε β=	3, 2,023,100.00	5, 151,550.00
. %	-5, 1, 2, . 5 . 15	-313,3.0,/5.5/

#### **Statements of Cash Flows of the Company (Continued)**

J .€ - M 2014

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
r** r m , . , rb.		
r** rmbm	50,000,000.00	
r** r m , b		
A Tale tale to the contract of	1, . / , . 3,/, 3. 1	5, 5, 1. 0
r m	2,32/, . 3,/, 3. 1	5, 5, 1, 1, 0
r % %%m.%		
r. % rb/. % ,.r . r .%(%), m.%.	10, 1, , , 55,55	10, 500,000.00
7. At 13	1,/55,2,/ 33.	/ 02, ,0 2
, r β r m ≯	1, 5, 3, 2, 1.	. 0, ,1, , ,0, , , 2
	3.,5/1,351.	-2, ,211, 0/.22
IV. Effects of exchange rate fluctuations on cash and cash equivalents	,125, 5, .51	_5,5, 2, , 3.31
V. Net increase of cash and cash equivalents	$-1^{5},11,^{5}/2.11$	_5, 2,1, , , 32, ,
and the second second	5 <sub>1.,2.2,3/</sub> 51	2,0.0, .1,0/3.3.
VI. Closing balance of cash and cash equivalents	50, 1, 5, 03. 0	1, . / , . 1,5 <sup>5</sup> 0 3

\* F G G G